HCV and the hepatic lipid pathway as a potential treatment target

Atherosclerosis has been described as a liver disease of the heart [1] . The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major foc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2011-12, Vol.55 (6), p.1428-1440
Hauptverfasser:	Bassendine, Margaret F, Sheridan, David A, Felmlee, Daniel J, Bridge, Simon H, Toms, Geoffrey L, Neely, R. Dermot G
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Apolipoproteins A - metabolism Apolipoproteins B - metabolism Apolipoproteins E - metabolism Biological and medical sciences Cholesterol Chronic Chylomicrons - metabolism Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen Hepacivirus - metabolism Hepacivirus - pathogenicity Hepatitis C Hepatitis C - metabolism Hepatitis C - therapy Hepatitis C - virology Human viral diseases Humans Hypolipidemic Agents - therapeutic use Infectious diseases Lipid Metabolism - drug effects Lipoproteins Lipoproteins, VLDL - metabolism Liver - metabolism Medical sciences Metabolic Networks and Pathways Models, Biological Pharmacology. Drug treatments Triglycerides Viral diseases Viral hepatitis VLDL
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!